Welcome to the Cipla Stock Liveblog, your real-time source for the latest updates and comprehensive analysis on a prominent ...

Stay up-to-date with the Cipla Stock Liveblog, your trusted source for real-time updates and thorough analysis of a prominent ...

The India business of the brokerage's coverage companies grew 10.2% YoY to Rs 207 billion in Q4 FY25 driven by better pricing ...

March quarter earnings brought relief to the Indian stock market as corporate performance exceeded estimates. Nifty 50 ...

With Cipla's shares showing a gain of 0.55% to reach Rs 1,481.30, the stock reflects ongoing market activity in the ...

Cipla's India operations certified water positive by Bureau Veritas. Reduced water withdrawal by 13.1% and 50% water recycled ...

Key pharma stocks, including Granules India and Gland Pharma, have shown substantial recovery, with the Nifty Pharma index ...

The leading 30 pharmaceutical companies, with revenues above Rs 2,500 crore, have registered robust net profit growth of 31 per cent during the financial year 2024-25 on account of new product ...

Drug major Cipla has received approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard ...

The presence of multinational pharma companies (MNCs) in India's drug market continues to shrink, reaching 14.5% in May 2025 ...

Here is a list of companies scheduled to announce dividends, including their ex-dividend dates for final and special ...

Theravance Biopharma and Mylan settle a patent dispute with Eugia Pharma over Yupelri, delaying generic entry until 2039.